|
HMP19 is a new metastasis suppressor in epithelial ovarian cancer |
|
View Full Text View/Add Comment Download reader |
DOI:10.46701/APJBG.2018032018112 |
KeyWord:HMP19, human epithelial ovarian cancer, immunohistochemistry, qRT-PCR, prognosis |
Author | Institution |
Yuanlin Liu |
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Shuang Liu |
Department of Clinical Bio-Bank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Yingjing Wang |
Department of Clinical Bio-Bank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Min Su |
Department of Clinical Bio-Bank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Yuquan Zhang |
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Xiaoqin Liu |
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Feng Yao |
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
Yunzhao Xu |
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China |
|
Hits: 2483 |
Download times: 2088 |
Abstract: |
HMP19 is a neuron-specific gene; its expression product belongs to a family of neuronal proteins which can be found in numerous kinds of human cancers. However, the clinicopathological significance of HMP19 expression in epithelial ovarian cancer (EOC) is as yet unknown. In this study, protein expression levels of HMP19 in cancerous tissues were determined by tissue microarray immunohistochemistry analysis (TMA-IHC) (n = 117). HMP19 protein levels in cancer tissues were associated with clinical characteristics and overall survival rates of patients with EOC. It was found that both mRNA and protein levels of HMP19 were significantly lower in EOC than those in normal ovary or fallopian tube tissues (P<0.05). The protein expression level of HMP19 was significantly associated with a lower FIGO stage, a lower level of CA-125 and a lower presence of metastasis. Consistent with related adverse clinical pathological features, the overall survival (OS) rate of patients with low or non HMP19-expressing tumors was inferior compared to those with high HMP19-expressing tumors. This is in accordance with further studies that found high HMP19 protein level to be an independent prognostic factor for OS in EOC. Multivariate analysis demonstrated that tumor patients with low HMP19 expression had an exceedingly
poor OS. HMP19 plays a role in metastasis/tumor suppression and offers a prognostic value for EOC. HMP19, as a new inhibitor, strongly inhibits metastasis and partially attenuates tumor growth in EOC. |
Close |
|
|
|